HR Execs on the Move

GenapSys

www.genapsys.com

 
GenapSys is a company focused on the advancement of universal access to genomic information by delivering an affordable, scalable, and accurate genomic sequencing ecosystem that empowers both academic and clinical research applications. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for a wide range of applications. GenapSys is headquartered in Redwood City, CA. GenapSys products are provided for Research Use Only. Not for use in diagnostic procedures.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.genapsys.com
  • 200 Cardinal Way Third Floor
    Redwood, CA USA 94063
  • Phone: 800.796.7710

Executives

Name Title Contact Details
Ishan Tsay
Director, Software Products Profile
Surekha Karudapuram
VP, Product Management and Marketing Profile
Ryan Walters
Chief Product Officer Profile
Holly Baden-Tillson
Vice President of Customer Experience Profile
Lissa Nakhwa
Director of Marketing Profile

Similar Companies

Bonna-Agela Technologies

Bonna-Agela Technologies is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Allyis Inc

Allyis Inc is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intralytix

Intralytix, Inc. is a biotechnology company focused on the production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Aduro Biotech

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro`s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro`s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.